INO Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -95.02%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 374.12%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $39.29 which suggests that it could grow by 479.44%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.618, which suggesting that the stock is 61.808% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.17%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 357.84x versus 2.16x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Capricor Therapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -63.94%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 374.12%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $50.80 which suggests that it could grow by 113.09%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.618, which suggesting that the stock is 61.808% more volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.221, suggesting its less volatile than the S&P 500 by 77.875%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Capricor Therapeutics, Inc. quarterly revenues of --. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 357.84x versus 97.23x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -12425.36%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 374.12%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Perspective Therapeutics, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.618, which suggesting that the stock is 61.808% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 357.84x versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -36.3%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Myomo, Inc.'s return on equity of -68.35%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 374.12%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 410.1%. Given that Myomo, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Myomo, Inc. is more attractive than Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.618, which suggesting that the stock is 61.808% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 357.84x versus 0.97x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.